120 related articles for article (PubMed ID: 16397207)
1. Mouse Models of Human Cancers Consortium Workshop on Nervous System Tumors.
Gutmann DH; Maher EA; Van Dyke T
Cancer Res; 2006 Jan; 66(1):10-3. PubMed ID: 16397207
[TBL] [Abstract][Full Text] [Related]
2. Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop.
Gutmann DH; Stiles CD; Lowe SW; Bollag GE; Furnari FB; Charest AL
Neuro Oncol; 2011 Jul; 13(7):692-9. PubMed ID: 21727208
[TBL] [Abstract][Full Text] [Related]
3. Mouse models of human cancer consortium symposium on nervous system tumors.
Gutmann DH; Baker SJ; Giovannini M; Garbow J; Weiss W
Cancer Res; 2003 Jun; 63(11):3001-4. PubMed ID: 12782610
[TBL] [Abstract][Full Text] [Related]
4. Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop.
Reilly KM; Rubin JB; Gilbertson RJ; Garbow JR; Roussel MF; Gutmann DH
Cancer Res; 2008 Jul; 68(14):5508-11. PubMed ID: 18632599
[No Abstract] [Full Text] [Related]
5. Applications of mouse glioma models in preclinical trials.
Hu X; Holland EC
Mutat Res; 2005 Aug; 576(1-2):54-65. PubMed ID: 16011838
[TBL] [Abstract][Full Text] [Related]
6. Can mouse models for brain tumors inform treatment in pediatric patients?
Weiss WA; Banerjee A
Semin Cancer Biol; 2004 Feb; 14(1):71-7. PubMed ID: 14757537
[TBL] [Abstract][Full Text] [Related]
7. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
8. Testing of new agents in childhood cancer preclinical models: meeting summary.
Houghton PJ; Adamson PC; Blaney S; Fine HA; Gorlick R; Haber M; Helman L; Hirschfeld S; Hollingshead MG; Israel MA; Lock RB; Maris JM; Merlino G; Patterson W; Reynolds CP; Shannon K; Yu A; Yu J; Smith MA
Clin Cancer Res; 2002 Dec; 8(12):3646-57. PubMed ID: 12473573
[TBL] [Abstract][Full Text] [Related]
9. Mouse models of brain tumors and their applications in preclinical trials.
Fomchenko EI; Holland EC
Clin Cancer Res; 2006 Sep; 12(18):5288-97. PubMed ID: 17000661
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer in mice and man: the Penn Workshop 2004.
Hruban RH; Rustgi AK; Brentnall TA; Tempero MA; Wright CV; Tuveson DA
Cancer Res; 2006 Jan; 66(1):14-7. PubMed ID: 16397208
[TBL] [Abstract][Full Text] [Related]
12. Pioneering models of pediatric brain tumors.
Grigore FN; Yang SJ; Chen CC; Koga T
Neoplasia; 2023 Feb; 36():100859. PubMed ID: 36599191
[TBL] [Abstract][Full Text] [Related]
13. Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes.
Ebben JD; You M
Int J Biochem Cell Biol; 2016 Sep; 78():288-296. PubMed ID: 27474492
[TBL] [Abstract][Full Text] [Related]
14. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
Lefer DJ; Bolli R
J Cardiovasc Pharmacol Ther; 2011; 16(3-4):332-9. PubMed ID: 21821536
[TBL] [Abstract][Full Text] [Related]
15. High-grade glioma mouse models and their applicability for preclinical testing.
de Vries NA; Beijnen JH; van Tellingen O
Cancer Treat Rev; 2009 Dec; 35(8):714-23. PubMed ID: 19767151
[TBL] [Abstract][Full Text] [Related]
16. Roles and potential clinical applications of intermediate filament proteins in brain tumors.
Quick Q; Paul M; Skalli O
Semin Pediatr Neurol; 2015 Mar; 22(1):40-8. PubMed ID: 25976260
[TBL] [Abstract][Full Text] [Related]
17. [Animal models of human glioma: the progress of application and investigation].
Zhu HF; Zhang YX; Zhao XD
Dongwuxue Yanjiu; 2012 Jun; 33(3):337-42. PubMed ID: 22653863
[TBL] [Abstract][Full Text] [Related]
18. Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.
Kumar S; Mokhtari RB; Yeger H; Baruchel S
Expert Opin Drug Discov; 2012 Nov; 7(11):1093-106. PubMed ID: 22998522
[TBL] [Abstract][Full Text] [Related]
19. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum.
Weiss WA; Israel M; Cobbs C; Holland E; James CD; Louis DN; Marks C; McClatchey AI; Roberts T; Van Dyke T; Wetmore C; Chiu IM; Giovannini M; Guha A; Higgins RJ; Marino S; Radovanovic I; Reilly K; Aldape K
Oncogene; 2002 Oct; 21(49):7453-63. PubMed ID: 12386807
[TBL] [Abstract][Full Text] [Related]
20. Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.
LeBlanc AK; Mazcko C; Brown DE; Koehler JW; Miller AD; Miller CR; Bentley RT; Packer RA; Breen M; Boudreau CE; Levine JM; Simpson RM; Halsey C; Kisseberth W; Rossmeisl JH; Dickinson PJ; Fan TM; Corps K; Aldape K; Puduvalli V; Pluhar GE; Gilbert MR
Neuro Oncol; 2016 Sep; 18(9):1209-18. PubMed ID: 27179361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
